Elsevier Launches Molecular Oncology
First issue online in May 2007
Amsterdam, 14 May 2007 – Elsevier announced today the inaugural issue of a new journal, Molecular Oncology – a journal for discovery-driven translational cancer research, published by Elsevier on behalf of the Federation of European Biochemical Societies (FEBS). The quarterly journal will focus on the advances in the rapidly expanding field of molecular oncology. The first issue will appear online today and be available in print in the first week of June 2007.
Prof. Julio E.Celis, Scientific Director of the Institute of Cancer Biology at the Danish Cancer Society in Copenhagen, will be the founding Editor-in-Chief of the new journal. A prestigious international Board of Editors including Profs. Mariano Barbacid, Minna Bissell, Peter Boyle, Tony Hunter, John Mendelsohn, Joan Massague, Richard Schilsky, Jane Visvader, Hironobu Sasano, and Axel Ullrich, who will be actively involved in developing the editorial policy of the journal.
Molecular Oncology will highlight new discoveries, approaches, as well as technical developments, in basic, clinical and discovery-driven translational research. A main feature of the journal will be to provide an international forum for debating cancer issues, and for integrating the input of all the stakeholders.
Editor-in-Chief Prof. Julio E. Celis explains: "The completion of the human genome project, as well as the current availability of novel and powerful technologies within genomics, proteomics and functional genomics promise to have a major impact on clinical practice, as these developments are likely to change the way in which cancer will be diagnosed, treated and monitored in the future.The greatest challenge today is how to effectively bridge basic and clinical cancer research in order to expedite the translation of novel discoveries into clinical applications for the benefit of the patient."
"The Danish Cancer Society with its 380,000 members, and various patient support and research departments is proud to host the Editorial Office of this exciting new journal in cancer", states A. Rohliged, Director, and former Minister of Health in Denmark.
Elsevier’s presence in the field of oncology with leading titles such as Cancer Cell, The Lancet Oncology, European Journal of Cancer, BBA Reviews on Cancer and many additional journals of high prestige, continues to expand to keep pace with growing interest in the topic. Elsevier is proud to be partnering with one of the leading life science federations in Europe on this new journal.
The first content of the journal can be found on ScienceDirect, using the following link: http://www.sciencedirect.com/science/journal/15747891.
# # #
About Editor-in-Chief, Julio E. Celis
Julio E. Celis is Professor and Director of the Institute of Cancer Biology at the Danish Cancer Society and is generally recognized as one of the founding fathers of proteomics. Celis' group in Copenhagen has pioneered the use of proteomics to the analysis of bladder and breast cancer and introduced the concept of discovery-driven translational cancer research. Julio Celis is currently Secretary General of the Federation of European Biochemical Societies (FEBS), and was President of the Initiative for Science in Europe (ISE) until February this year. Website: http://proteomics.cancer.dk/ e-mail: firstname.lastname@example.org.
The Federation of European Biochemical Societies, since its inception in 1964, has promoted life sciences and supported scientists in Europe and elsewhere, and is one of the largest not-for-profit organizations in life sciences today. FEBS offers its members advance courses, fellowships and participation in their annual Congress. All activities related to FEBS are financed by income generated by their three publications: FEBS Letters, FEBS Journal and Molecular Oncology. Their mission is to foster scientific excellence and promote science for society. For more information on FEBS, a registered charity in the UK, visit www.febs.org.
Elsevier is a world-leading provider of information solutions that enhance the performance of science, health, and technology professionals, empowering them to make better decisions, deliver better care, and sometimes make groundbreaking discoveries that advance the boundaries of knowledge and human progress. Elsevier provides web-based, digital solutions — among them ScienceDirect, Scopus, Research Intelligence and ClinicalKey— and publishes over 2,500 journals, including The Lancet and Cell, and more than 35,000 book titles, including a number of iconic reference works. Elsevier is part of RELX Group, a world-leading provider of information and analytics for professional and business customers across industries. www.elsevier.com
Phone: +31 (0) 20 485 3836